Biochem/physiol Actions

Chemokineligand 20 (CCL20) is chemotactic for immature dendritic cells, effector or memory CD4⁺T lymphocytes and B lymphocytes. CCR6 (C-C chemokine receptor type 6), the receptor of CCL20, plays a vital role in the progression of several diseases, such as tumors, rheumatoid arthritis, pneumococcal meningitis and human renal inflammation.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

General description

Chemokineligand 20 (CCL20) is also called as liver and activation-regulated chemokine, macrophage inflammatory protein-3α (MIP-3α) or exodus-1. It is a cysteine−cysteine chemokine, that is located on human chromosome 2q36. It is expressed at high levels in serum or IgA1 and HMC incubation system. The CCL20 promoter region consists of a transcription start site, a nuclear factor (NF)-κB binding site, a CCAAT/enhancer-binding proteins binding site, an activator protein-1 binding sites and a specificity protein 1 (Sp1)-binding site.

Immunogen

Peptide with sequence CLGYTDRILHPK, from the internal region of the protein sequence according toNP_004582.1; NP_001123518.1

Physical form

Supplied at 0.5 mg/mL in 20mM Tris (pH 7.3) and 150mM NaCl with 0.02% sodium azide and 0.5% bovine serum albumin.